Urothelial carcinoma, arising from the transitional epithelium lining the urinary bladder, ureters, and renal pelvis, is the most common malignancy of the urinary tract and the fourth most common cancer in men in developed countries. Bladder cancer represents the most frequent presentation of urothelial carcinoma, with an estimated 570,000 new diagnoses globally each year. The disease presents as a spectrum from non muscle invasive disease, which is associated with high recurrence rates but generally favorable survival outcomes with appropriate endoscopic and intravesical treatment, to muscle invasive and metastatic disease, which carries significantly worse prognosis and requires systemic treatment. Metastatic urothelial carcinoma has historically been associated with poor outcomes, with platinum based chemotherapy producing objective responses in approximately 50 percent of eligible patients but median overall survival rarely exceeding 15 months.
A critical challenge in urothelial carcinoma management is the high prevalence of comorbidities including renal impairment, cardiovascular disease, and advanced age in affected patients, many of whom are ineligible for cisplatin based chemotherapy, the most effective conventional cytotoxic regimen. The proportion of newly diagnosed metastatic urothelial carcinoma patients ineligible for cisplatin is estimated at 30 to 50 percent, creating a substantial population for whom the optimal first line treatment has historically been carboplatin gemcitabine, a less effective alternative, or best supportive care. The development of immune checkpoint inhibitors and antibody drug conjugates has transformed the treatment landscape for cisplatin ineligible patients and for those with platinum refractory disease, providing new therapeutic options with distinct mechanisms and meaningful clinical benefits.
PD L1 Expression and Immunobiology in Bladder Cancer
Urothelial carcinoma displays several features that support its responsiveness to immune checkpoint inhibition. The disease is characterized by one of the highest somatic mutation rates of any solid tumor, particularly in the subset associated with tobacco exposure, generating numerous neoantigens that can be recognized by T cells and predicting immunogenicity. PD L1 expression on both tumor cells and tumor infiltrating immune cells is common in urothelial carcinoma and has been evaluated as a predictive biomarker for immunotherapy response, though its predictive value has proved more complex and context dependent than initially anticipated. The tumor infiltrating lymphocyte density and overall immune gene expression profiles of urothelial carcinomas provide additional immunological information that influences treatment responsiveness.
FGFR3 mutations, present in approximately 20 percent of muscle invasive and metastatic urothelial carcinomas, represent an important actionable molecular alteration that defines a distinct tumor subset with specific targeted treatment options. FGFR3 altered tumors tend to have lower immune infiltration and lower PD L1 expression compared to FGFR3 wild type tumors, potentially explaining their relative resistance to immunotherapy monotherapy and supporting the use of FGFR inhibitors as targeted therapy in this molecular subgroup. Comprehensive molecular profiling of urothelial carcinoma has identified multiple additional targetable alterations including ERBB2 amplification and TSC1 mutations that are being evaluated in biomarker driven clinical trials.
Pembrolizumab in Platinum Refractory Urothelial Carcinoma
The KEYNOTE 045 trial established pembrolizumab as a standard second line treatment for patients with advanced urothelial carcinoma that had progressed after platinum containing chemotherapy. The trial randomized 542 patients to pembrolizumab at 200 milligrams every three weeks or investigator’s choice of paclitaxel, docetaxel, or vinflunine. Pembrolizumab demonstrated superior overall survival with a hazard ratio of 0.73 and a median overall survival of 10.3 months compared to 7.4 months for chemotherapy, with a particularly pronounced benefit in patients with high PD L1 combined positive scores. The objective response rate was 21 percent with pembrolizumab compared to 11 percent with chemotherapy, and crucially, responses to pembrolizumab were substantially more durable than those to chemotherapy.
The durability advantage of pembrolizumab over chemotherapy was one of the most clinically meaningful findings from KEYNOTE 045. While most responses to single agent chemotherapy in platinum refractory urothelial carcinoma are short lived, complete and partial responses to Keytruda frequently persisted for many months and in some patients for years, reflecting the immunological memory generated by successful T cell mediated tumor control. This durability, combined with the more favorable tolerability profile of pembrolizumab compared to taxane chemotherapy in an often elderly and comorbid patient population, established pembrolizumab as the preferred second line treatment for platinum refractory urothelial carcinoma.
First Line Pembrolizumab for Cisplatin Ineligible Patients
The KEYNOTE 052 trial evaluated pembrolizumab monotherapy as first line treatment for patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin based chemotherapy. Among 370 enrolled patients, pembrolizumab produced an objective response rate of 29 percent in the overall population, with a 47 percent response rate in patients with PD L1 combined positive scores of ten or greater. Complete response rates of approximately 8 percent were observed, and a meaningful proportion of responders maintained their responses for over two years. These results provided the evidence basis for regulatory approval of pembrolizumab as first line monotherapy for cisplatin ineligible patients with high PD L1 expression and as an alternative for patients ineligible for any platinum based chemotherapy.
The evolving treatment landscape for first line metastatic urothelial carcinoma has become increasingly complex with the addition of novel agents and combination strategies. Maintenance pembrolizumab following platinum based chemotherapy, evaluated in the JAVELIN Bladder 100 trial using avelumab as the checkpoint inhibitor, established the concept of immune checkpoint maintenance in urothelial carcinoma. The combination of pembrolizumab with enfortumab vedotin, an antibody drug conjugate targeting Nectin 4, has demonstrated remarkable activity in phase III trials with overall response rates exceeding 60 percent and significant overall survival benefits compared to platinum based chemotherapy, potentially establishing a new frontline standard for cisplatin eligible patients that integrates immunotherapy with targeted cytotoxicity.
Non Muscle Invasive Bladder Cancer and BCG Unresponsive Disease
The application of pembrolizumab has expanded beyond metastatic disease to the treatment of non muscle invasive bladder cancer that is unresponsive to bacillus Calmette Gu茅rin intravesical immunotherapy. The KEYNOTE 057 trial evaluated pembrolizumab in patients with BCG unresponsive, high risk non muscle invasive bladder cancer who had declined or were ineligible for radical cystectomy. Complete response rates of approximately 41 percent at three months were observed in the cohort with carcinoma in situ with or without papillary disease, with a meaningful proportion of complete responders maintaining their responses at 12 months. This result provided an important non surgical treatment option for patients with high risk non muscle invasive disease failing BCG who wished to preserve their bladder.
The integration of Keytruda into the BCG unresponsive non muscle invasive bladder cancer setting addresses a significant unmet clinical need, as this patient population faces the difficult choice between radical cystectomy, which is the standard of care but carries substantial morbidity, and continued conservative management with limited effective alternative options. The availability of effective systemic immunotherapy for BCG unresponsive disease creates an opportunity to achieve durable bladder preservation in patients who respond, while identifying those who require cystectomy based on treatment failure before disease progression compromises surgical outcomes.
Conclusion
Urothelial carcinoma treatment has been significantly advanced by the introduction of pembrolizumab across multiple clinical settings, from BCG unresponsive non muscle invasive disease to platinum refractory metastatic carcinoma. Keytruda has established itself as a standard of care in second line metastatic urothelial carcinoma and as an effective option for cisplatin ineligible patients in the first line setting. The development of highly effective combination strategies incorporating pembrolizumab with antibody drug conjugates promises to further transform outcomes in this disease, building on the immunotherapy foundation that pembrolizumab has established to deliver increasingly effective and durable anti tumor activity for a patient population with historically limited treatment options.
